Cell Signaling & Oncology

Axon Ligands™ for Cell Signaling & Oncology Research

The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].

Cell Signaling and Oncology products Library

For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.

Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.

Axon Ligands™ for Epigenetic research   Axon 5051 - Cell signaling and Oncology Library.xls                   


[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.

20 Item(s)

per page
Axon ID Name Description From price
1539 AT 7519 mesylate CDK inhibitor €80.00
1966 AZD5438 CDK inhibitor (1, 2, and 9 specific) €80.00
3228 CDK inhibitor CR8 Potent CDK inhibitor (1, 2, 5, 7, and 9 specific) €130.00
1776 Dinaciclib CDK inhibitor (1, 2, 5, and 9 specific) €90.00
2273 LEE 011 Orally bioavailable and highly selective small-molecule inhibitor of CDK4/6 €70.00
1494 MK 1775 Wee1 kinase inhibitor €80.00
2695 NSC 23005 sodium Novel small molecule inhibitor of INK4C (p18(INK4C) or p18) €90.00
1243 NSC 625987 CDK4 inhibitor €95.00
2052 Palbociclib isethionate Orally active cyclin-dependent kinase (CDK4/6) inhibitor €125.00
1505 PD0332991 hydrochloride CDK4 and CDK6 inhibitor €80.00
3693 PF-06873600 CDK inhibitor (4, 6, and 8 specific) Inquire
1983 R 547 CDK inhibitor (1, 2, and 4 specific) €95.00
1530 RO 3306 CDK1 inhibitor €80.00
1614 SNS 032 CDK inhibitor (2, 7 and 9 specific) €85.00
3184 SR-4835 Potent, highly selective and orally bioavailable dual CDK12/CDK13 inhibitor €130.00
1765 TG003 Inhibitor of Cdc2-like kinase (Clk) family €110.00
3560 THZ1 Covalent CDK7 inhibitor €60.00
3561 THZ1 dihydrochloride Covalent CDK7 inhibitor €110.00
3402 THZ531 First-in-class, potent, selective, covalent CDK12/CDK13 inhibitor €130.00
3535 XY028-140 Potent and selective CDK4/6 inhibitor; PROTAC €120.00

20 Item(s)

per page
Please wait...